Business ❯ Healthcare ❯ Pharmaceuticals

Manufacturing

Eli Lilly Active Pharmaceutical Ingredients Radioligand Therapy Expansion Sterile Pharmaceuticals West Pharmaceutical Services Company Investments Biologics Manufacturing Facilities Nutraceuticals Takeovers Anlon Healthcare Ltd. SteriPort and SVP Sterile Liquid Products Peptide Manufacturing Investment Rubicon Research Syringe Production Cold Chain Storage Facility Development AstraZeneca CSL Limited Food-Grade Iron Phosphate Product Distribution Excipients Safety Cell Therapy Cell and Gene Therapy Novo Nordisk Innovation Drug Delivery Systems Data Security Contact Lenses AbbVie Local Production

Eli Lilly Breaks Ground on $6.5 Billion Houston Campus to Make Oral GLP-1 Pill

The company says the Generation Park site will boost domestic drug production and train local workers while state incentives support the deal.

Johnson & Johnson Commits More Than $1 Billion to Expand Acuvue Capacity

AbbVie to Build $1.4 Billion Injectable-Medicines Campus in Durham, N.C.

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

Novartis to Build 46,000‑Square‑Foot Radioligand Therapy Plant in Denton, Texas

Johnson & Johnson to Build $1 Billion Cell Therapy Plant in Pennsylvania

Eli Lilly Chooses Pennsylvania for $3.5 Billion Plant to Produce Weight-Loss Injectables

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

BD Invests $110 Million to Launch Neopak Syringe Production in Nebraska

AstraZeneca Invests $2 Billion to Expand Maryland Biologics and Build New Clinical Site

Novartis Opens Carlsbad Radioligand Therapy Plant as U.S. Buildout Accelerates

Cencora Commits Over $1 Billion to U.S. Drug Distribution Buildout Through 2030

Eli Lilly Unveils $3 Billion Netherlands Plant to Scale Production of Oral Weight‑Loss Pill